Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cullinan Therapeutics Inc (CGEM)

Cullinan Therapeutics Inc (CGEM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Cullinan Therapeutics Announces New Preclinical Data for CLN-978 and Global Phase 1b Study in Systemic Lupus Erythematosus

Cullinan will present new preclinical data for CLN-978 and details of a Phase 1b study in lupus at ACR 2024.Quiver AI SummaryCullinan Therapeutics, Inc. announced that it will present new preclinical data...

CGEM : 15.30 (-3.10%)
Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024

CGEM : 15.30 (-3.10%)
Cullinan Therapeutics: Q3 Earnings Snapshot

Cullinan Therapeutics: Q3 Earnings Snapshot

CGEM : 15.30 (-3.10%)
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

CGEM : 15.30 (-3.10%)
Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference

CGEM : 15.30 (-3.10%)
Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024

CGEM : 15.30 (-3.10%)
Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus

CGEM : 15.30 (-3.10%)
REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

/PRNewswire/ -- Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Oncology, Inc., announced today the launch of the REZILIENT3 trial...

CGEM : 15.30 (-3.10%)
Why Shares of Cullinan Oncology Jumped This Week

The company's presentation at a conference got the attention of analysts and investors.

CGEM : 15.30 (-3.10%)
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2022 Financial Results

Completed agreement for strategic collaboration to jointly develop and commercialize CLN-081 with Taiho Pharmaceutical Presented updated Phase 1/2a data...

CGEM : 15.30 (-3.10%)

Barchart Exclusives

2 Energy Dividend Stocks to Buy This November for Growth and Income
For investors seeking steady gains, these two dividend-paying energy stocks could be smart picks. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar